Last reviewed 2026-04-20 · How we verify

High dose of MRM-3379

Mirum Pharmaceuticals, Inc. · Phase 2 active Small molecule Quality 0/100

High dose of MRM-3379 is a Small molecule drug developed by Mirum Pharmaceuticals, Inc.. It is currently in Phase 2 development.

At a glance

Generic name	High dose of MRM-3379
Sponsor	Mirum Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

High dose of MRM-3379 CI brief — competitive landscape report
High dose of MRM-3379 updates RSS · CI watch RSS
Mirum Pharmaceuticals, Inc. portfolio CI

Frequently asked questions about High dose of MRM-3379

What is High dose of MRM-3379?

High dose of MRM-3379 is a Small molecule drug developed by Mirum Pharmaceuticals, Inc..

Who makes High dose of MRM-3379?

High dose of MRM-3379 is developed by Mirum Pharmaceuticals, Inc. (see full Mirum Pharmaceuticals, Inc. pipeline at /company/mirum-pharmaceuticals-inc).

What development phase is High dose of MRM-3379 in?

High dose of MRM-3379 is in Phase 2.

Manufacturer: Mirum Pharmaceuticals, Inc. — full pipeline
Compare: High dose of MRM-3379 vs similar drugs
Pricing: High dose of MRM-3379 cost, discount & access